New therapeutic approaches to achieve the desired blood pressure goal

Cardiovascular Reviews and Reports

Volumn 18, Issue 12, 1997, Pages 10-16

  Makrilakis, Konstantinos ^a   Bakris, George L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; CLONIDINE; CREATININE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE PLUS FELODIPINE; FELODIPINE; HYDRALAZINE; HYDRALAZINE PLUS HYDROCHLOROTHIAZIDE PLUS RESERPINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; METHYLDOPA; METOPROLOL; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RESERPINE; SPIRONOLACTONE; TEXZAM; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC NEPHROPATHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; KIDNEY FUNCTION; PRACTICE GUIDELINE; REVIEW;

EID: 0031465444     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Burt VL, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
2. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. In press.
3. Epstein M, Bakris GL. Newer approaches to antihypertensive therapy: use fixed dose combination therapy Arch Intern Med. 1996;156:1969-1978.
4. Fogari R, Zoppi A, Mugellini A, et al. Effect of benazepril plus amlodipine vs. benazepril alone on urinary albumin excretion in hypertensive patients with type II diabetes and microalbuminuria. Clin Drug Invest. 1996:11:50-55.
5. Bakris GL, Griffin KA, Picken MM, et al. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertension 1997;15. In press.
6. Bakris GL, Weir M, DeQuattro V, et al. Renal effects of a long acting ACEI, trandolapril or nondihydropyridine calcium blocker, verapamil alone or in a fixed dose combination in diabetic nephropathy: A randomized double blind placebo controlled multicenter study. Nephrology. 1997;3:271[abstract]
7. Munter K, Hergenroder S, Jochims K, et al. Individual and combined effects of verapamil or trandolapril on glomerular morphology and function in the stroke prone rat. J Am Soc. Nephrol. 1996;7:681-686.
8. Cruickshank JM, Lewis J, Moore V, et al. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Human Hypertens. 1992;6:85-90.
9. Lewis EJ, Hunsicker LG, Bain RP, et al for the Collaborative Study Group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329: 1456-1462.
10. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med. 1996;156:286-289.
11. Lebovitz HE, Wiegmann TB, Cnaan A. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria Kidney Int Suppl. 1994;45:S150-S155.
12. Slataper R, Vicknair N, Sadler R, et al. ACE inhibition normalizes renal size and microalbuminuria in normotensive insulin dependent diabetic patients. J Diabetes Complications. 1994;8:2-6.
13. Viberti G; Mogensen CE; Groop LC; et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group JAMA. 1994;271(4):275-9.
14. Hebert LA, Bain RP, Verme D, et al for the Collaborative Study Group. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int. 1994;46:1688-1693.
15. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650.
16. Valentino V, Wilson M, Weart W, et al. Effects of calcium antagonists and angiotensin converting enzyme inhibitors on diabetic nephropathy: Archives of Int. Med. 1991;151:2367-2374.
17. Bakris GL. Renal effects of calcium antagonists in diabetes mellitus: An overview of studies in animal models and in humans. Am J Hypertens. 1991;4(Suppl II):487S-493S.
18. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
19. Hall J. Intrarenal action of converting enzyme inhibitors. Am J Hypertens. 1989,2:875-884.
20. Bakris GL. Microalbuminuria: Prognostic implications. Curr Opin Nephrol Hypertens 1996;5:219-223.
21. Bakris GL. Hypertension in diabetic patients: An overview of interventional studies to preserve renal function. Am J Hypertens. 1993;6(4):140S-147S.
22. Bakris GL, Mehler P, Schrier R. Hypertension and Diabetes. In: Schrier RW, Gottschalk CW (eds). Diseases of the Kidney. 6th Ed., Little Brown; 1996;1455-1464.
23. Dworkin LD, Tolbert E , Recht PA, et al. Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension. 1996;27(2):245-250
24. Anderson S, Rennke HG, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int. 1992;41(4):891-897.
25. Remuzzi G, Ruggenenti P, Benegni A. Understanding the nature of renal disease progression Kidney Int. 1997;51:2-15.
26. Rossing P, Tarnow L, Boelskifte S, et al. Differences between nisoldipine and lisinopril in glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997;46:481-487.
27. Gaber L, Walton C, Brown S, et al. Effect of antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994;46.161-169.
28. Brown S, Walton C, Crawford P, et al. Comparative renal hemodynamic effects of an ACEI or calcium antagonist on progression of diabetic nephropathy in the dog. Kidney Int. 1993;43:1210-1216
29. Anderson S. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension. 1991;17:288-295.
30. Picken M, Griffin K, Bakris GL, et al. Comparative effects of four different calcium antagonists on progression of renal disease in a remnant kidney model. J Am Soc Nephrol. 1996;7:1586(abstract).
31. Bakris GL, Mangrum A, Copley JB, et al. Calcium channel or beta blockade on progression of diabetic renal disease in African-Americans. Hypertension. 1997;29:744-750.
32. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996;45:216-222.
33. Zucchelli P, Auzccala A, Borghi M, et al. Long term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney In.t. 1992;42:452-458.
34. Jerums G. ACE inhibition versus calcium channel blockade in normotensive type I and type II diabetic patients with microalbuminuria. Nephrol Dial Transplant.. In press.
35. Weidmann P, Schneider M, Bohlen L, et al. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis. Nephrol Dial Transplant. 1995;10:1963-1974.
36. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963-1974.
37. Maki DD, Ma JZ, Louis TA, et al. Effects of antihypertensive agents on the kidney. Arch Intern Med. 1995;155:1073-1082.
38. Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium channel blockers. Nephrol Dial Transplant. In press.
39. Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol. 1989;256:F1015-1020.
40. Fioretto P, Frigato F, et al. Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens. 1992;5:837-846.
41. Lash J, Bakris GL. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995;10(suppl 9): 56-62.
42. Hess B. Reduced proteinuria after cessation of long acting osmotic release nifedipine GITS in diabetic nephropathy. Nephrol Dial Transplant. 1997;12:1772(letter).
43. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
44. Kober L, Torp-Pederson C, Clarsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
45. Packer M, O Connor CM, Ghali JK, et al for the Prospective Randomized Amlodipine Survival Evaluation Study Group: Effect of Amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-1114.
46. Hansen JF , Hagerup L , Sigurd B , et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Am J Cardiol. 1997;Mar 15;79(6):738-41.
47. Hansen JF, Hagerup L, Sigurd B, et al. Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). J Hypertens. 1997;15(2):S119-122.
48. Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynamic and metabolic effects of low dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens. 1995;8:461-466.
49. Walker WG, Hermann JA, Anderson JE. Randomized doubly blinded trial of enalapril vs. Hydrochlorothiazide on glomerular filtration rate in diabetic nephropathy. Hypertension. 1993;22:410(abstract).
50. The Enalapril-Hydrochlorothiazide in Essential Hypertension Canadian Working Group. Enalapril and enalapril-hydrochlorothiazide in the treatment of essential hypertension. Clin Ther. 1993;15:364-373.
51. Vaisse B, Renucci JF, Delage Y, et al. Evaluation of the antihypertensive efficacy of lisinopril and captopril associated with hydrochlorothiazide by ambulatory measurement of arterial pressure. Ann Cardiol Angeiol. (Paris) 1993;42:566-572.
52. Mayaudon H, Chanudet X, Janin G, et al. Comparison of the efficacy of enalapril + hydrochlorothiazide and captopril + hydrochlorothiazide combinations in mild to moderate arterial hypertension by ambulatory measurement of blood pressure. Ann Cardiol Angeiol. (Paris) 1995;44:235-241.
53. Bakris GL, Wilson DM, Burnett JC Jr. The renal forearm and hormonal responses to standing in the presence and absence of propranolol Circulation. 1986;74:1061-1065.
54. Prisant LM, Weir MR, Papademetriou V, e al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J. 1995;130:359-366.
55. Frishman WH, Mrczek WJ, et al. First-line therapy option with low dose bisoprolol fumarate and low dose hydrochlorothiazide in patients with stage I and stage II svstemic hypertension. J Clin Pharmacol. 1995;35:182-188.
56. Dahlof B, Jonsson L, Borgholst O, et al. Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone. Blood Pressure 1993;2(suppl 1):37-45.